Leap Services, Inc. operates a retail-as-a-service platform designed to support consumer brands in establishing their physical store presence. Founded in 2018 and headquartered in Chicago, the company facilitates store development and operations by providing the necessary infrastructure, including physical space, staffing, and technology management. Leap's platform aims to enhance the retail experience by creating a seamless, omnichannel environment that caters to customer preferences. The company manages retail locations in major cities such as New York City, San Francisco, Chicago, and Miami, positioning itself as a key player in transforming the retail landscape for high-growth brands.
Metagenomi, Inc. is a genetic medicines company based in Emeryville, California, focused on developing innovative gene editing systems for the treatment of genetic diseases. Since its incorporation in 2016, the company has utilized a proprietary metagenomics-derived genome editing toolbox that enables the creation of curative therapeutics. This toolbox encompasses a range of advanced technologies, including programmable nucleases, base editors, and various RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CASTs). Metagenomi aims to address the challenges posed by diverse mutations that have traditionally been difficult to target with existing genome engineering approaches.
Checkr, Inc. is a technology company that specializes in background check services. Founded in 2014 and headquartered in San Francisco, California, Checkr offers a range of screening services, including criminal record checks, driving checks, and identity verification, all delivered through an advanced platform that can provide faster turnaround times compared to traditional background check providers. The company utilizes artificial intelligence and machine learning to enhance the hiring process, ensuring compliance and improving the applicant experience. Checkr serves various industries, including financial services, healthcare, retail, and technology, by providing tools that help organizations navigate the complexities of workforce dynamics while promoting transparency and fairness in hiring. Additionally, Checkr offers security solutions, continuous monitoring, and a unified identity verification service, Checkr Connect IDV, which integrates identity verification with background checks.
Arctic Wolf Networks, Inc. specializes in providing security operations center-as-a-service to businesses, aiming to mitigate cyber risk. Founded in 2012 and headquartered in Eden Prairie, Minnesota, the company delivers a range of solutions including Managed Detection and Response, Managed Risk, and Managed Cloud Monitoring. These services are facilitated by a concierge security team that acts as an extension of a company's internal resources, offering tailored threat detection, response, and ongoing risk management. Arctic Wolf's platform incorporates cloud infrastructure monitoring, software application monitoring, dynamic asset identification, vulnerability assessments, and account takeover risk detection. Additionally, the company has developed the Arctic Wolf Agent, which collects actionable intelligence from IT environments. Arctic Wolf serves various industries, including financial services, healthcare, and legal sectors, with additional offices located in Provo, Utah, and Waterloo, Canada.
DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.
Bombas LLC is a New York-based company that designs, manufactures, and markets premium quality athletic socks for men, women, teens, and girls. Founded in 2013, Bombas offers a variety of products, including ankle, calf, and multipack socks, as well as underwear and t-shirts. The company is dedicated to providing comfortable, soft, and durable apparel at affordable prices. In addition to its focus on quality, Bombas is committed to social responsibility, with a mission to help those in need. It sells its products through an online platform, reaching customers both in the United States and internationally.
Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.
InterVenn Biosciences Inc. is a biotechnology company that specializes in artificial intelligence-based mass spectrometry technology for glycoproteomics. Founded in 2017 and headquartered in South San Francisco, California, with additional offices in the Philippines, Malaysia, and Australia, InterVenn focuses on the identification, quantification, and classification of glycoproteomic signals in human blood and tissue. Its VISTA platform is the first commercially available system that assesses protein glycosylation in a site-specific manner, enabling the discovery of biomarkers for various conditions, including cancers, autoimmunity, fibrosis, and neurodegeneration. The company's technology aims to facilitate early cancer detection and improve patient care through actionable insights derived from glycoproteomic analysis.
Genomatica, Inc. specializes in developing innovative manufacturing processes that convert renewable feedstocks into intermediate and basic chemicals. Utilizing its proprietary biotechnology platform, the company engineers microorganisms to facilitate fermentation-based production, focusing on a pipeline of 20 key chemicals, including butanediol and butadiene. Genomatica has established itself as a leader in bioengineering, aiming to foster a transition to sustainable materials. Its technology has gained recognition for commercializing processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is important in cosmetics and personal care products. The company is also advancing research in bio-nylon. Genomatica's achievements have been acknowledged through several awards, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol. Founded in 1998 and headquartered in San Diego, California, Genomatica focuses on enhancing the economics, sustainability, and performance of chemical production.
Cybereason Inc. develops a comprehensive cybersecurity platform focused on endpoint protection, including endpoint detection and response, anti-ransomware, anti-malware, and antivirus solutions. Founded in 2012 by a team of elite intelligence professionals, the company offers a suite of products designed to detect, analyze, and respond to cyber threats. Key offerings include Deep Detect & Respond, which analyzes behavioral data to identify suspicious activities; Deep Prevent, aimed at blocking advanced attacks; Deep Investigate, which collects enterprise data for threat analysis; and Deep Respond, a threat detection and response interface. Additionally, Cybereason provides RansomFree, an anti-ransomware solution, alongside various services such as monitoring, investigation, and training. The company is headquartered in Boston and maintains offices in London, Tel Aviv, and Tokyo, leveraging a custom-built in-memory graph to enhance its threat detection capabilities.
BioTheryX, Inc. is a biopharmaceutical company based in Chappaqua, New York, that specializes in the development of therapies for hematological malignancies and other diseases. The company focuses on restoring protein homeostasis through innovative approaches such as Protein Homeostatic Modulators, which are small molecular glue cereblon binders with significant therapeutic potential. Additionally, BioTheryX is advancing targeted protein degradation technologies, including PROTACs, which utilize dual ligands to facilitate the degradation of specific proteins. The company also offers BTX-A51, an oral small molecule that acts as a multi-kinase inhibitor to target leukemic stem cells and suppress key oncogenic gene transcription. Founded in 2007, BioTheryX aims to expedite the delivery of effective therapies to patients with unmet medical needs by leveraging enhanced biology-driven models and clinically proven translational approaches.
LUMICKS B.V. is a company that specializes in developing advanced equipment for dynamic single-molecule and cell avidity analysis, facilitating research in biology and cancer at the molecular and cellular levels. Founded in 2014 and headquartered in Amsterdam, with an additional office in Cambridge, Massachusetts, LUMICKS offers innovative technologies such as correlative optical tweezers-fluorescence microscopy systems and the C-Trap, which integrates optical tweezers with advanced imaging techniques. The company’s Acoustic Force Spectroscopy (AFS) enables the study of mechanical properties in biological systems, while its u-Flux microfluidics system allows for single-molecule experiments in controlled laminar flow environments. By enabling live measurements and imaging of molecular interactions, LUMICKS provides valuable insights into the fundamental causes of diseases, including cancer, and supports drug optimization efforts.
Crossover Health, Inc. is a healthcare provider focused on delivering comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010 and headquartered in Aliso Viejo, California, the company operates health centers in various locations, including Silicon Valley. Crossover Health offers a wide range of services, such as primary care, urgent care, preventive care, chronic disease management, health education, physical therapy, and remote care, among others. By integrating various health and wellness benefits with technology-enabled services, Crossover Health aims to enhance access to care and reduce healthcare costs for companies. The firm collaborates closely with client partners to customize health services based on health analytics, fostering a culture of health ownership among employees while improving both the quality of care and the overall employee experience.
AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Model Medicines is a company focused on accelerating drug development through the integration of human expertise and artificial intelligence. Utilizing its ActivPred AI Drug Discovery Platform, Model Medicines applies machine learning to model chemistry and human biology, which facilitates the discovery of therapeutics that can be repositioned for treating complex diseases. The company has developed a robust pipeline of patent-pending therapeutics targeting various medical conditions, including oncology, infectious diseases, neurological disorders, and gastric disorders. By leveraging drug development data alongside advanced AI techniques, Model Medicines aims to expedite the clinical trial process, allowing new drugs to enter trials within a matter of months, thereby enhancing the efficiency and effectiveness of drug development for healthcare institutions.
NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, that specializes in developing innovative immuno-therapeutics using its proprietary Artificial Immune (AIM) technology. Founded in 2011, the company focuses on orchestrating specific immune responses to treat various conditions, including cancer, inflammation, viral diseases, transplant rejection, and autoimmunity. NexImmune's lead products include AIM101, an injectable therapy targeting specific solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in clinical trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma, both designed to harness the body's T cells for a targeted immune response with potential curative effects.
Imago BioSciences is a clinical-stage biotechnology company based in San Carlos, California, focused on developing innovative therapies for hematologic diseases, including leukemia and myelodysplastic syndromes. Established in 2012, the company specializes in small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme crucial for blood cell production in the bone marrow. Its lead candidate, Bomedemstat, is an orally available inhibitor of LSD1, being evaluated for its potential to modify the disease course in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers. Imago aims to translate advanced scientific insights into effective treatments that can significantly improve the quality and duration of life for patients facing these challenging conditions.
Private Equity Round in 2020
Prometheus Biosciences, formerly known as Prometheus Laboratories, is a biotechnology company focused on developing and commercializing innovative pharmaceutical and diagnostic products, primarily for gastrointestinal diseases such as inflammatory bowel disease (IBD). Based in San Diego, California, the company offers a range of diagnostic tests, including Anser IFX, Anser ADA, and IBD sgi Diagnostic, which enable healthcare providers to monitor treatment and optimize patient care. Prometheus also markets therapeutic agents, such as Entocort EC and Imuran, for managing conditions like Crohn's disease and rheumatoid arthritis. Additionally, it provides genetic and serologic testing for celiac disease and lactose intolerance, among other disorders. With a commitment to precision medicine, Prometheus aims to enhance individualized patient care through its advanced diagnostic capabilities and therapeutic solutions. The company was founded in 1995 and operates as a subsidiary of Precision IBD, Inc.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders associated with neuronal imbalance. The company's lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently undergoing Phase IIa clinical trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy, and a program for KCNT1 GOF epilepsy. The company engages in collaborations and licensing agreements with various partners, including RogCon Inc., Purdue Neuroscience Company, and Ionis Pharmaceuticals. Founded in 2015, Praxis Precision Medicines is headquartered in Cambridge, Massachusetts.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Rubrik is a data security solutions provider that caters to a diverse range of organizations, from large enterprises to mid-sized businesses. The company specializes in data management and recovery, offering a platform designed to enhance cyber resilience, which includes improving both cyber posture and recovery capabilities. By integrating enterprise data management with web-scale IT, Rubrik eliminates the need for traditional backup software, enabling businesses to efficiently manage increasing volumes of data across both private and public clouds. This innovative approach allows organizations to recover data swiftly and supports their digital transformation efforts, ultimately fostering greater business agility.
FAASOS, operated by Rebel Foods Services, is an on-demand food delivery platform that primarily functions through a mobile app. It is transforming the way customers order and receive food, serving approximately 10,000 customers daily, with a rapidly increasing user base. The service is currently available in ten cities, focusing exclusively on app-based orders to enhance customer convenience and streamline the delivery process. As a pioneer in the food tech space, FAASOS continues to expand its reach and improve its offerings to meet the growing demand for quick and accessible food delivery solutions.
ThredUp Inc. operates an online consignment and thrift store, specializing in the buying and selling of new and used apparel. Founded in 2009 and based in Oakland, California, the platform offers a wide range of clothing for women, maternity, children, and accessories, including handbags and shoes. ThredUp aims to promote sustainable fashion by encouraging consumers to consider secondhand options first, facilitating access to over 35,000 brands at significantly reduced prices. The company has developed a robust marketplace and infrastructure that has already redistributed nearly 100 million garments, catering to millions of users who utilize the platform to sell their clothes or purchase items through various options such as online browsing, physical stores, or try-before-you-buy boxes. ThredUp's innovative approach positions it as a key player in the growing resale economy.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatment. Founded in 2014 and based in South San Francisco, California, the company is advancing several product candidates, including ORIC-101, a small molecule antagonist of the glucocorticoid receptor associated with resistance to various cancer therapies in solid tumors. Another key candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, which plays a significant role in resistance to chemotherapy and immunotherapy regimens. In addition to these, ORIC is working on multiple precision medicines aimed at addressing other cancer resistance mechanisms. The company's founders, Charles Sawyers and Scott Lowe, are recognized for their contributions to identifying novel cancer targets that have led to innovative treatment options.
FAASOS, operated by Rebel Foods Services, is an on-demand food delivery platform that primarily functions through a mobile app. It is transforming the way customers order and receive food, serving approximately 10,000 customers daily, with a rapidly increasing user base. The service is currently available in ten cities, focusing exclusively on app-based orders to enhance customer convenience and streamline the delivery process. As a pioneer in the food tech space, FAASOS continues to expand its reach and improve its offerings to meet the growing demand for quick and accessible food delivery solutions.
Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to understand and manipulate gene expression to develop innovative therapies for various diseases, particularly cancer. Foghorn is advancing several drug candidates, including FHD-286, an enzymatic inhibitor targeting BRG1 and BRM for acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader aimed at treating synovial sarcoma. Additionally, the company has ongoing preclinical and discovery programs targeting non-small-cell lung cancer and other cancers associated with ARID1B mutations. Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to create novel oncology therapeutics. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics is pioneering a new class of drug targets that could transform treatment approaches for patients with serious diseases.
Pearl, Inc., operating as Pearl Health, specializes in artificial intelligence technology tailored for the dental industry. Founded in 2019 and headquartered in West Hollywood, California, the company has developed several innovative tools to enhance dental practices. Its offerings include Second Opinion, a computer vision platform for identifying dental pathologies; Smart Margin, which aids in the dental restoration process; and Scan Clarity Score, a tool that evaluates patient scans based on margin clarity. Additionally, Pearl provides Practice Intelligence, software that analyzes office-specific data to improve decision-making. By enabling practitioners to access comprehensive data and automate laboratory tasks, Pearl aims to improve the efficiency, accuracy, and overall quality of dental care.
PAX Labs, Inc. specializes in the manufacture of high-quality, app-controlled vaporizers for loose-leaf and concentrated substances. The company's product line includes the PAX 3, PAX 2, and PAX Era, along with a variety of accessories designed to enhance the user experience. PAX also provides a mobile application that allows users to customize their vaporization experience, promoting quality and transparency in cannabis consumption. Founded in 2004 and based in San Francisco, California, PAX Labs has established itself as an industry leader through innovation and thoughtful design. The company distributes its products through a network of retailers and distributors both domestically and internationally, as well as through its online platform.
As of October 31, 2020, was acquired by BR Brands, LLC, in a reverse merger transaction.
Anaplan, Inc. is a provider of a cloud-based connected planning platform designed to enhance collaboration and decision-making across various business functions, including finance, sales, supply chain, marketing, and human resources. The platform integrates different database structures, allowing organizations to create and utilize models in a unified manner. Anaplan operates under a subscription model and offers its services over the Internet, in addition to providing professional services such as consulting, implementation, and training to support users in leveraging the platform effectively. Founded in 2008 and headquartered in San Francisco, Anaplan has a global presence with offices in multiple countries and a network of expert partners, catering to large and fast-growing organizations seeking to streamline their planning processes.
Rumble Fitness, LLC specializes in boxing-inspired fitness classes designed to enhance physical conditioning and build confidence. Founded in 2016 and based in New York, Rumble combines high-intensity interval training, strength training, and metabolic conditioning to create a comprehensive workout experience. In addition to its classes, Rumble offers various products online, including boxing classes, gift cards, wraps, bottled water, and rental gloves, catering to both fitness enthusiasts and newcomers to boxing. The company's unique approach to fitness aims to help individuals achieve a lean and strong physique through engaging and dynamic workouts.
Bombas LLC is a New York-based company that designs, manufactures, and markets premium quality athletic socks for men, women, teens, and girls. Founded in 2013, Bombas offers a variety of products, including ankle, calf, and multipack socks, as well as underwear and t-shirts. The company is dedicated to providing comfortable, soft, and durable apparel at affordable prices. In addition to its focus on quality, Bombas is committed to social responsibility, with a mission to help those in need. It sells its products through an online platform, reaching customers both in the United States and internationally.
Instacart is a grocery delivery service that enables customers to receive groceries and home essentials at their doorstep, often within an hour. Founded in 2012 and headquartered in San Francisco, Instacart offers a wide selection of over 500,000 items from various local grocery stores, including well-known retailers such as Safeway, Whole Foods, and Costco. Customers can conveniently combine products from multiple stores into a single order, making the shopping experience more efficient. The company connects customers with individual shoppers who fulfill their orders, allowing for a personalized service. Instacart has garnered significant funding from various prominent investment firms, supporting its growth and expansion in the competitive grocery delivery market.
Lyft is an on-demand transportation service that connects riders with drivers through a mobile application, allowing users to request rides and make payments seamlessly. Founded in June 2012 in San Francisco, Lyft has become the second-largest ridesharing provider in the U.S. and Canada, serving approximately 95 percent of the U.S. population. The platform offers various ride options, including traditional private rides, shared rides, and luxury vehicles. In addition to standard ride-sharing services, Lyft has expanded into the bike and scooter-sharing market, promoting multimodal transportation solutions. The service is particularly popular among college, university, and corporate communities, and it allows riders to schedule rides up to seven days in advance.